217 related articles for article (PubMed ID: 28801346)
1. Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension.
Avouac J; Konstantinova I; Guignabert C; Pezet S; Sadoine J; Guilbert T; Cauvet A; Tu L; Luccarini JM; Junien JL; Broqua P; Allanore Y
Ann Rheum Dis; 2017 Nov; 76(11):1931-1940. PubMed ID: 28801346
[TBL] [Abstract][Full Text] [Related]
2. Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis.
Ruzehaji N; Frantz C; Ponsoye M; Avouac J; Pezet S; Guilbert T; Luccarini JM; Broqua P; Junien JL; Allanore Y
Ann Rheum Dis; 2016 Dec; 75(12):2175-2183. PubMed ID: 26961294
[TBL] [Abstract][Full Text] [Related]
3. The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis.
Derrett-Smith E; Clark KEN; Shiwen X; Abraham DJ; Hoyles RK; Lacombe O; Broqua P; Junien JL; Konstantinova I; Ong VH; Denton CP
Arthritis Res Ther; 2021 Sep; 23(1):234. PubMed ID: 34488870
[TBL] [Abstract][Full Text] [Related]
4. Role of Stromelysin 2 (Matrix Metalloproteinase 10) as a Novel Mediator of Vascular Remodeling Underlying Pulmonary Hypertension Associated With Systemic Sclerosis.
Avouac J; Guignabert C; Hoffmann-Vold AM; Ruiz B; Dorfmuller P; Pezet S; Amar O; Tu L; Van Wassenhove J; Sadoine J; Launay D; Elhai M; Cauvet A; Subramaniam A; Resnick R; Hachulla E; Molberg Ø; Kahan A; Humbert M; Allanore Y
Arthritis Rheumatol; 2017 Nov; 69(11):2209-2221. PubMed ID: 28805015
[TBL] [Abstract][Full Text] [Related]
5. Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis.
Maurer B; Reich N; Juengel A; Kriegsmann J; Gay RE; Schett G; Michel BA; Gay S; Distler JH; Distler O
Ann Rheum Dis; 2012 Aug; 71(8):1382-7. PubMed ID: 22523431
[TBL] [Abstract][Full Text] [Related]
6. Transforming growth factor-β plays divergent roles in modulating vascular remodeling, inflammation, and pulmonary fibrosis in a murine model of scleroderma.
Tsujino K; Reed NI; Atakilit A; Ren X; Sheppard D
Am J Physiol Lung Cell Mol Physiol; 2017 Jan; 312(1):L22-L31. PubMed ID: 27864286
[TBL] [Abstract][Full Text] [Related]
7. T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis.
Boleto G; Guignabert C; Pezet S; Cauvet A; Sadoine J; Tu L; Nicco C; Gobeaux C; Batteux F; Allanore Y; Avouac J
Arthritis Res Ther; 2018 Aug; 20(1):197. PubMed ID: 30157927
[TBL] [Abstract][Full Text] [Related]
8. Effects of thymosin β4 and its N-terminal fragment Ac-SDKP on TGF-β-treated human lung fibroblasts and in the mouse model of bleomycin-induced lung fibrosis.
Conte E; Iemmolo M; Fruciano M; Fagone E; Gili E; Genovese T; Esposito E; Cuzzocrea S; Vancheri C
Expert Opin Biol Ther; 2015; 15 Suppl 1():S211-21. PubMed ID: 26098610
[TBL] [Abstract][Full Text] [Related]
9. 2-methoxyestradiol attenuates bleomycin-induced pulmonary hypertension and fibrosis in estrogen-deficient rats.
Tofovic SP; Zhang X; Jackson EK; Zhu H; Petrusevska G
Vascul Pharmacol; 2009; 51(2-3):190-7. PubMed ID: 19540933
[TBL] [Abstract][Full Text] [Related]
10. The D prostanoid receptor agonist BW245C [(4S)-(3-[(3R,S)-3-cyclohexyl-3-hydroxypropyl]-2,5-dioxo)-4-imidazolidineheptanoic acid] inhibits fibroblast proliferation and bleomycin-induced lung fibrosis in mice.
van den Brule S; Wallemme L; Uwambayinema F; Huaux F; Lison D
J Pharmacol Exp Ther; 2010 Nov; 335(2):472-9. PubMed ID: 20719937
[TBL] [Abstract][Full Text] [Related]
11. The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis.
Wettstein G; Luccarini JM; Poekes L; Faye P; Kupkowski F; Adarbes V; Defrêne E; Estivalet C; Gawronski X; Jantzen I; Philippot A; Tessier J; Tuyaa-Boustugue P; Oakley F; Mann DA; Leclercq I; Francque S; Konstantinova I; Broqua P; Junien JL
Hepatol Commun; 2017 Aug; 1(6):524-537. PubMed ID: 29404476
[TBL] [Abstract][Full Text] [Related]
12. Long-term treatment with fasudil improves bleomycin-induced pulmonary fibrosis and pulmonary hypertension via inhibition of Smad2/3 phosphorylation.
Bei Y; Hua-Huy T; Duong-Quy S; Nguyen VH; Chen W; Nicco C; Batteux F; Dinh-Xuan AT
Pulm Pharmacol Ther; 2013 Dec; 26(6):635-43. PubMed ID: 23928001
[TBL] [Abstract][Full Text] [Related]
13. C-type natriuretic peptide ameliorates pulmonary fibrosis by acting on lung fibroblasts in mice.
Kimura T; Nojiri T; Hino J; Hosoda H; Miura K; Shintani Y; Inoue M; Zenitani M; Takabatake H; Miyazato M; Okumura M; Kangawa K
Respir Res; 2016 Feb; 17():19. PubMed ID: 26895702
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast-specific perturbation of transforming growth factor beta signaling provides insight into potential pathogenic mechanisms of scleroderma-associated lung fibrosis: exaggerated response to alveolar epithelial injury in a novel mouse model.
Hoyles RK; Khan K; Shiwen X; Howat SL; Lindahl GE; Leoni P; du Bois RM; Wells AU; Black CM; Abraham DJ; Denton CP
Arthritis Rheum; 2008 Apr; 58(4):1175-88. PubMed ID: 18383385
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib, a Small-Molecule Kinase Inhibitor, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice.
Huang X; Wang W; Yuan H; Sun J; Li L; Wu X; Luo J; Gu Y
Tohoku J Exp Med; 2016 Aug; 239(4):251-61. PubMed ID: 27439438
[TBL] [Abstract][Full Text] [Related]
16. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis.
Huang J; Maier C; Zhang Y; Soare A; Dees C; Beyer C; Harre U; Chen CW; Distler O; Schett G; Wollin L; Distler JHW
Ann Rheum Dis; 2017 Nov; 76(11):1941-1948. PubMed ID: 28814429
[TBL] [Abstract][Full Text] [Related]
17. Intrinsic defence capacity and therapeutic potential of natriuretic peptides in pulmonary hypertension associated with lung fibrosis.
Baliga RS; Scotton CJ; Trinder SL; Chambers RC; MacAllister RJ; Hobbs AJ
Br J Pharmacol; 2014 Jul; 171(14):3463-75. PubMed ID: 24641440
[TBL] [Abstract][Full Text] [Related]
18. EM703 improves bleomycin-induced pulmonary fibrosis in mice by the inhibition of TGF-beta signaling in lung fibroblasts.
Li YJ; Azuma A; Usuki J; Abe S; Matsuda K; Sunazuka T; Shimizu T; Hirata Y; Inagaki H; Kawada T; Takahashi S; Kudoh S; Omura S
Respir Res; 2006 Jan; 7(1):16. PubMed ID: 16438734
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of transforming growth factor-β via the activin receptor-like kinase-5 inhibitor attenuates pulmonary fibrosis.
Koh RY; Lim CL; Uhal BD; Abdullah M; Vidyadaran S; Ho CC; Seow HF
Mol Med Rep; 2015 May; 11(5):3808-13. PubMed ID: 25585520
[TBL] [Abstract][Full Text] [Related]
20. JAK2 mediates lung fibrosis, pulmonary vascular remodelling and hypertension in idiopathic pulmonary fibrosis: an experimental study.
Milara J; Ballester B; Morell A; Ortiz JL; Escrivá J; Fernández E; Perez-Vizcaino F; Cogolludo A; Pastor E; Artigues E; Morcillo E; Cortijo J
Thorax; 2018 Jun; 73(6):519-529. PubMed ID: 29440315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
